


Curriculum vitae

Name: **Poon** Ming Chun Darren

Email: mc_poon@clo.cuhk.edu.hk

Phone: +852 29171200



Introduction:

Dr Darren Ming-Chun Poon is the Honorary Clinical Associate Professor at the Chinese University of Hong Kong and the Honorary Consultant in Clinical Oncology at both the Hong Kong Sanatorium & Hospital and Prince of Wales Hospital, Hong Kong.

Dr Poon has several specialist areas of expertise, which include genitourinary (GU) cancer, neuro-oncology, hepato-pancreatic cancer, and head and neck cancer. His research interests include novel therapies for GU cancers, image-guided radiotherapy and stereotactic body radiotherapy (SBRT) for prostate, central nervous system tumor, pancreatic and liver cancer. Dr Poon pioneered the use of SBRT in the treatment of prostate cancer in Hong Kong and completed the first-in-Asia randomized study for prostate SBRT. He has published more than 50 original papers, scientific reviews, and abstracts in peer-reviewed journals and has co-authored the 10th edition of Fast Facts: Prostate Cancer. He is one of the expert panel members in the Advanced Prostate Cancer Consensus Conference (APCCC) from 2019 onwards, and the Asia Pacific Advanced Prostate Cancer Consensus Conference (APAC-APCCC) from 2020 onwards. Dr Poon has been an invited speaker at local and regional, and international conferences and is currently involved in several clinical trials investigating new therapies for urothelial, bladder, renal and prostate cancers.

In addition to his clinical and academic duties, Dr Poon has been Vice-President of several professional societies, including the Hong Kong Society of Uro-Oncology, Hong Kong Nasopharyngeal Carcinoma Study Group and the Hong Kong SBRT study group. In addition, he is a Council Member of the Hong Kong Prostate Foundation and Vice-Chairman of the Hand in Hand Cancer Foundation.

Qualifications

- 2012: Fellow of the Hong Kong Academy of Medicine (FHKAM (Radiology))
- 2012: Fellow of the Hong Kong College of Radiologists (FHKCR)
- 2009: Fellow of the Royal College of Radiologists (FRCR)
- 2002: Bachelor of Medicine and Surgery (MBChB). The Chinese University of Hong Kong

Sub-specialization

- Genitourinary Cancer
- Neuro-oncology (including spinal metastasis)
- Head and Neck Cancer
- Hepato-pancreatic cancer

Position Held

- Resident at Department of Clinical Oncology, PWH (July 2003 – Dec 2011)
- Resident specialist at Department of Clinical Oncology, PWH (Jan 2012 – Oct 2013)
- Associate consultant at Department of Clinical Oncology, PWH (Nov 2013 – Jan 2017)
- Consultant at Department of Clinical Oncology, PWH (Feb 2017 – Feb 2020)
- Honorary Consultant in Clinical Oncology, Hong Kong Sanatorium & Hospital (Mar 2020 – now)
- Honorary Consultant in Clinical Oncology, Prince of Wales Hospital, Hong Kong (Mar 2020 - now)
- Honorary clinical assistant professor, CUHK (Nov 2013 – Dec 2017)
- Honorary clinical associate professor, CUHK (Jan 2018 – now)

- Member, QA subcommittee, Central Coordinating Committee in Clinical Oncology, Hospital Authority (Jan 2017 – Feb 2020)

- Convener, GU cancer Site-Specific Expert Advisory Groups (COC oncology), Hospital Authority (Apr 2016 – Feb 2020)

- Vice-President, The Hong Kong Nasopharyngeal carcinoma study group (Oct 2018 – 2021)
- Vice-President, The Hong Kong Society of Uro-Oncology (Jul 2015 – now)
- Vice-President, The Hong Kong SBRT study group (Jul 2018- now)

- Council member, The Hong Kong Prostate Foundation (Jul 2016 – now)
- Vice-chairman, The Hand in Hand Cancer Foundation (Jul 2016 - now)

Award

- The Best Abstract Presentation at 15th Urological Association of Asia (UAA) Congress, 2017 (The preliminary efficacy and tolerability of chemohormonal therapy in metastatic hormone-naive prostate cancer – the first Asia’s real life experience)
- The best proffered paper presentation in 18th annual scientific meeting of Hong Kong College of Radiologists, 2010 (Intensity modulated radiotherapy for prostate cancer: toxicity and biochemical control in 183 Chinese patients from Single institutions in Hong Kong)

Education & Training

- Teaching in HKCR/FRCR part II training course, HKCR/HKCR (2009 – now)
- Teaching in urology trainee training course, Hong Kong Urology Association (2009 – now)
- Coordinator of radiation therapist’s contouring workshop, PWH (2016 – 2020)
- Invited speaker of the HA commissioned training for the radiation therapists (2018)

Administrative experience and qualification

- Cyberknife training course certification, Hong Kong Sanatorium & Hospital (2017)
- Head & Neck Ultrasound course 2018 certification, CUHK (2018)
- Management program 101 for new leaders, HA (2015)
- Secretary for Clinical Oncology team, PWH (2009 – 2011)
- Members, working group for Linear accelerator replacement, PWH (2016 – 2020)
- Editor, management guideline for prostate cancer, head and neck cancer, GBM, brain metastasis, and spinal metastasis, PWH (2009 – 2020)

Book

Kirby, Roger S, Patel, Manish I, Poon, Darren M.C.

Fast Facts: Prostate Cancer. If, when and how to intervene 10th edition ISBN: 978-3-318-06587-9

Publications

- Poon DMC et al. 1.5T Magnetic Resonance-Guided Stereotactic Body Radiotherapy for Localized Prostate Cancer: Preliminary Clinical Results of Clinician- and Patient-Reported Outcomes. Cancers (Basel). 2021 Sep 28;13(19):4866.
- Poon DMC et al. Prospective Randomized Phase II Study of Stereotactic Body Radiotherapy (SBRT) vs. Conventional Fractionated Radiotherapy (CFRT) for Chinese Patients with Early-Stage Localized

Prostate Cancer. *Curr. Oncol.* 2022, 29, 27-37

- Poon DMC, Yang B, Geng H, Wong OL, Chiu ST, Cheung KY, Yu SK, Chiu G, Yuan J. Analysis of online plan adaptation for 1.5T magnetic resonance-guided stereotactic body radiotherapy (MRgSBRT) of prostate cancer. *J Cancer Res Clin Oncol.* 2022 Feb 24;1–10.
- Poon DMC, Wu S, Ho L, Cheung KY, Yu B. Proton Therapy for Prostate Cancer: Challenges and Opportunities. *Cancers (Basel).* 2022 Feb 13;14(4):925
- Poon DMC, Chan K, Chan T, Cheung FY, Lam D, Lam M, Law KS, Lee C, Lee EKC, Leung A, Sze H, Tong CC, Wong KCW, Kwong P. Ethnic Pharmacogenomic Differences in the Management of Asian Patients with Metastatic Prostate Cancer. *Cancers (Basel).* 2022 Jan 14;14(2):407
- Wong OL, Poon DMC, Kam MKM, Lo GG, Fung WWK, Man SY, Xue C, Yu SK, Cheung KY, Yuan J. 3D-T2W-TSE radiotherapy treatment planning MRI using compressed sensing acceleration for prostate cancer: Image quality and delineation value. *Asia Pac J Clin Oncol.* 2022 Jan 24
- Xue C, Yuan J, Poon DMC, Zhou Y, Yang B, Yu SK, Cheung YK. Reliability of MRI radiomics features in MR-guided radiotherapy for prostate cancer: Repeatability, reproducibility, and within-subject agreement. *Med Phys.* 2021 Nov;48(11):6976-6986
- Xue C, Yuan J, Lo GG, Chang ATY, Poon DMC, Wong OL, Zhou Y, Chu WCW. Radiomics feature reliability assessed by intraclass correlation coefficient: a systematic review. *Quant Imaging Med Surg.* 2021 Oct;11(10):4431-4460
- Yuan J, Poon DMC, Lo G. Editorial for "Multi-site concordance of diffusion weighted imaging quantification for assessing prostate cancer aggressiveness". *J Magn Reson Imaging.* 2021 Nov 12. doi: 10.1002/jmri.27994
- Yang B, Yuan J, Cheung KY, Huang CY, Poon DMC, Yu SK. Magnetic Resonance-Guided Radiation Therapy of Patients With Cardiovascular Implantable Electronic Device on a 1.5 T Magnetic Resonance-Linac. *Pract Radiat Oncol.* 2022 Jan-Feb;12(1):e56-e61.
- A narrative review of MRI acquisition for MR-guided-radiotherapy in prostate cancer. Jing Yuan, Darren M. C. Poon, Gladys Lo, Oi Lei Wong, Kin Yin Cheung, Siu Ki Yu. *Quant Imaging Med Surg* 2022;12(2):1585-1607
- Gillessen, Attard, Beer T Poon DMC et al. Management of Patients with Advanced Prostate Cancer: Report of the Advanced Prostate Cancer Consensus Conference 2019. *Eur Urol.* 2020 Jan

- Fabio Turco.... D.M.C. Poon.... Gillessen, A. Omlin. What Experts Think About Prostate Cancer Management During the COVID-19 Pandemic: Report from the Advanced Prostate Cancer Consensus Conference 2021, Eur Urol 2022.
- Darren MC Poon et al. Consensus statements on the management of metastatic prostate cancer from the Hong Kong Urological Association and Hong Kong Society of Uro-Oncology. BJU Int Dec 2017
- Ma WK, Poon DMC et al. Consensus statements on the management of clinically localized prostate cancer from the Hong Kong Urological Association and the Hong Kong Society of Uro-Oncology. BJU Int Jan 2019
- Teoh JY, MacLennan S, Chan VW.... Poon DM et al. An International Collaborative Consensus Statement on En Bloc Resection of Bladder Tumour Incorporating Two Systematic Reviews, a Two-round Delphi Survey, and a Consensus Meeting. Eur Urol. 2020 May 7
- Darren MC Poon et al. Survival Outcomes, Prostate-Specific Antigen (PSA) Response, and Tolerance in First and Later Lines of Enzalutamide Treatment for Metastatic Castration-Resistant Prostate Cancer (mCRPC): a Real-World Experience in Hong Kong. *Clinical Genitourinary Cancer* 2018
- Darren MC Poon et al. Dosimetric Advantages And Superior Treatment Delivery Efficiency Of RapidArc Over Conventional Intensity-modulated Radiation Therapy In Radiation Therapy Planning For High Risk Prostate Cancer Involving Seminal Vesicles And Pelvic Nodes. Clin Oncol. 2013 Aug 15
- Darren MC Poon et al. Abiraterone acetate in metastatic castration-resistant prostate cancer - the unanticipated real-world clinical experience. BMC Urol. 2016 Mar
- Darren MC Poon et al. Lymph Node Response in a Patient with Metastatic Castration-resistant Prostate Cancer Treated With Radium-223. Clin Genitourin Cancer Nov 2017
- Poon DMC, Chan T, Chan K, et al. Preliminary efficacy and tolerability of chemohormonal therapy in metastatic hormone-naïve prostate cancer: The first real-life experience in Asia. Asia-Pac J Clin Oncol. 2018;1–6.
- Darren MC Poon, Ng J, Chan K. The importance of cycles of chemotherapy and post-docetaxel novel therapies in metastatic castration-resistant prostate cancer (mCRPC). Prostate Int. Feb 2015

- Darren MC Poon et al. Differences in Clinical Outcome Between Docetaxel and Abiraterone Acetate as the First-line Treatment in Chemo-Naïve Metastatic Castration-resistant Prostate Cancer (mCRPC) Patients with or without the Ineligible Clinical Factors of the COU-AA-302 Study. Prostate Int. Aug 2017
- Darren MC Poon et al. Management of advanced prostate cancer in Hong Kong: Insights from an APCCC-Derived survey. Asia Pac J Clin Oncol. 2019 Oct
- Darren MC Poon et al. The efficacy and toxicity of intensity-modulated radiation therapy for prostate cancer in Chinese patients. Hong Kong Med J. 2013 Jun 2009
- Darren MC Poon. Immunotherapy for urothelial carcinoma: Metastatic disease and beyond. Asia Pac J Clin Oncol. 2020 Sep
- Darren MC Poon et al. Prevention of docetaxel-associated febrile neutropenia with primary granulocyte colony-stimulating factor in Chinese metastatic hormone-sensitive and castration-resistant prostate cancer patients. Asia Pac J Clin Oncol 2021 Apr;17
- Darren MC Poon et al. Prostate cancer management in the era of COVID-19: Recommendations from the Hong Kong Urological Association and Hong Kong Society of Uro-oncology. Asia Pac J Clin Oncol 2021 Apr;15
- Darren MC Poon et al. Hong Kong Urological Association–Hong Kong Society of Uro-Oncology consensus statements on the management of advanced prostate cancer—2019 Updates. Asia Pac J Clin Oncol 2021 Apr;15
- Darren MC Poon et al. Consensus statements on the management of metastatic renal cell carcinoma from the Hong Kong Urological Association and the Hong Kong Society of Uro-Oncology 2019. Asia Pac J Clin Oncol 2021 Apr;15
- Chiong E, Murphy DG, Buchan NC, Chua MLK, Hakim L, Hamid AR, Hong SK, Horvath LG, Kanesvaran R, Khochikar M, Letran J, Lojanapiwat B, Malek R, Ng ACF, Vinh NT, Pang ST, Poon DMC, Ong TA, Saad M, Schubach K, Shiroki R, Türkeri L, Williams S, Wong A, Ye D; ANZUP Cancer Trials Group, Davis ID. Managing advanced prostate cancer in the Asia Pacific region: "Real-world" application of Advanced Prostate Cancer Consensus Conference 2019 statements. Asia Pac J Clin Oncol. 2022 Feb 8
- Darren MC Poon et al. Durability of the parotid-sparing effect of intensity-modulated radiotherapy

(IMRT) in early stage nasopharyngeal carcinoma: A 15-year follow-up of a randomized prospective study of IMRT versus two-dimensional radiotherapy. Head Neck 2021 Feb

- Lee TK, Poon DMC, Ng ACF et al. Cultural adaptation and validation of the Chinese version of the expanded prostate cancer index composite. Asia Pac J Clin Oncol. 2018 Mar;14 Suppl 1:10-15
- Teoh JY, Poon DMC et al. A territory-wide, multi-centre, age- and prostate-specific antigen-matched study comparing between chemohormonal therapy and hormonal therapy-alone in Chinese men with metastatic hormone-sensitive prostate cancer. Clin Genitourin Cancer Oct 2018
- Teoh JY, CF Ng, Poon DMC. Chemohormonal therapy for metastatic hormone-sensitive prostate cancer: An Asian perspective. Asia Pac J Clin Oncol. 2018 Nov;14 Suppl 5:5-8
- Teoh JY, Chiu PK, Chan SY, Poon DM et al. Androgen deprivation therapy, diabetes and poor physical performance status increase fracture risk in Chinese men treated for prostate cancer. Aging Male 2015 May
- Teoh JY, Chiu PK, Chan SY, Poon DM et al. Risk of cardiovascular thrombotic events after surgical castration versus gonadotropin-releasing hormone agonists in Chinese men with prostate cancer. Asian J Androl. 2014 Dec
- Teoh JY, Chiu PK, Chan SY, Poon DM et al. Risk of New-onset Diabetes after Androgen Deprivation Therapy for Prostate Cancer in the Asian Population. J Diabetes. 2014 Sep
- Teoh JY, Chan SY, Chiu PK, Poon DM et al. Risk of Acute Myocardial Infarction after Androgen Deprivation Therapy for Prostate Cancer in the Chinese Population. BJU Int 2014 Oct
- Teoh JY, Chan SY, Chiu PK, Poon DM et al. Risk of cardiovascular thrombotic events after surgical castration versus gonadotropin-releasing hormone agonists in Chinese men with prostate cancer. Asian J Androl 2014 Dec
- Teoh JY, Chan SY, Chiu PK, Poon DM et al. Risk of ischemic stroke after androgen deprivation therapy for prostate cancer in the Chinese population living in Hong Kong. Jpn J Clin Oncol. 2015 Feb
- Chan ATC, Hui EP, Ngan RKC, Tung SY, Cheng ACK, Ng WT, Lee VHF, Ma BBY, Cheng HC, Wong FCS, Loong HHF, Tong M, Poon DMC et al. Analysis of Plasma Epstein-Barr Virus DNA in Nasopharyngeal Cancer After Chemoradiation to Identify High-Risk Patients for Adjuvant Chemotherapy: A Randomized Controlled Trial. J Clin Oncol. 2018 Jul

- E P Hui, W F Li, B B Ma, W K J Lam, K C A Chan, F Mo, Q Y H Ai, A D King, C H Wong, R Guo, D M C Poon et al. Integrating Postradiotherapy Plasma Epstein-Barr Virus DNA and TNM Stage for Risk Stratification of Nasopharyngeal Carcinoma to Adjuvant Therapy. Ann Oncol 2020 Mar
- Edwin Pun Hui, Brigette B Y Ma, W K Jacky LamDarren M C Poon et al. Dynamic Changes of Post-Radiotherapy Plasma Epstein-Barr Virus DNA in a Randomized Trial of Adjuvant Chemotherapy Versus Observation in Nasopharyngeal Cancer. Clin Cancer Res 2021 Mar 10
- Au KH, Ngan RKC, Ng AWY, Poon DMC et al. Treatment outcomes of nasopharyngeal carcinoma in modern era after intensity modulated radiotherapy (IMRT) in Hong Kong: A report of 3328 patients (HKNPCSG 1301 study). Oral Oncol. 2018 Feb;77:16-21
- Ng WT, Lee MC, Fung NT, Wong EC, Cheung AK, Chow JC, Au KH, Poon DM et al. Dose volume effects of re-irradiation for locally recurrent nasopharyngeal carcinoma. Head Neck. 2019 Oct
- Ng WT, Wong ECY, Cheung AKW, Chow JCH, Poon DM et al. Patterns of care and treatment outcomes for local recurrence of NPC after definite IMRT-A study by the HKNPCSG. Head Neck. 2019 Oct
- Ng JTY, Yu KS, Poon DMC. Efficacy of endoscopy in assessing the local disease response in nasopharyngeal carcinoma patients after treated with intensity-modulated radiotherapy. Asia Pac J Clin Oncol. 2019 Oct 15
- Ai QY, King AD, Poon DMC et al. Extranodal extension is a criterion for poor outcome in patients with metastatic nodes from cancer of the nasopharynx. Oral Oncol. 2019 Jan
- Ai QY, King AD, Mo FKF, Law BKH, Bhatia KS, Ma BB, Poon DMC, Kam MKM. Prediction of distant metastases from nasopharyngeal carcinoma: Improved diagnostic performance of MRI using nodal volume in N1 and N2 stage disease. Oral Oncol. 2017 Jun
- Ai QY, Hu CW, Bhatia KS, Poon DMC et al. Nasopharyngeal carcinoma: relationship between invasion of the prevertebral space and distant metastases. Eur Arch Otorhinolaryngol 2017 Nov
- Qamar S, King AD, Ai QY, Law BKH, Chan JSM, Poon DMC et al. Amide proton transfer MRI detects early changes in nasopharyngeal carcinoma: providing a potential imaging marker for treatment response. Eur Arch Otorhinolaryngol. 2018 Dec 3
- Sahrish Qamar, Ann D King, Qi-Yong H Ai, Tiffany Y So, Frankie Kwok Fai Mo, Weitian Chen, Darren

M C Poon et al. Pre-treatment Intravoxel Incoherent Motion Diffusion-Weighted Imaging Predicts Treatment Outcome in Nasopharyngeal Carcinoma. Eur J Radiol 2020 Jun

- Sahrish Qamar, Ann D King, Qi-Yong H Ai, Tiffany Y So, Frankie Kwok Fai Mo, Weitian Chen, Darren M C Poon et al. Pre-treatment intravoxel incoherent motion diffusion-weighted imaging predicts treatment outcome in nasopharyngeal carcinoma. Eur J Radiol 2020 Aug
- Sahrish Qamar, Ann D King, Qi-Yong H Ai, Frankie Kwok Fai Mo, Weitian Chen, Darren M C Poon et al. Pre-treatment Amide Proton Transfer Imaging Predicts Treatment Outcome in Nasopharyngeal Carcinoma. Eur Radiol 2020 Jun
- Law BKH, King AD, Ai QY, Poon DMC et al. Head and Neck Tumors: Amide Proton Transfer MRI. Radiology. 2018 Sep
- Ai QY, King AD, Mo FKF, Law BKH, Bhatia KS, Poon DMC et al. Staging nodal metastases in nasopharyngeal carcinoma: which method should be used to measure nodal dimension on MRI? Clin Radiol. 2018 Jul
- Ai QY, King AD, Chan JSM, Chen W, Chan KCA, Woo JKS, Zee BCY, Chan ATC, Poon DMC et al. Distinguishing early-stage nasopharyngeal carcinoma from benign hyperplasia using intravoxel incoherent motion diffusion-weighted MRI. Eur Radiol. 2019 Mar
- Lun M Wong, Ann D King, Qi Yong H Ai, W K Jacky Lam, Darren M C Poon et al. Convolutional neural network for discriminating nasopharyngeal carcinoma and benign hyperplasia on MRI. Eur Radiol 2020 Nov
- Tiffany Y So, Qi-Yong H Ai, W K Jacky Lam, Sahrish Qamar, Darren M C Poon et al. Intravoxel incoherent motion diffusion-weighted imaging for discrimination of benign and malignant retropharyngeal nodes. Neuroradiology 2020 Dec
- Lun M Wong, Qi Yong H Ai, Frankie K F Mo, Darren M C Poon, Ann D King 1Convolutional neural network in nasopharyngeal carcinoma: how good is automatic delineation for primary tumor on a non-contrast-enhanced fat-suppressed T2-weighted MRI? Jpn J Radiol. 2021 Feb 5
- Wong LM, Ai QYH, Poon DMC, Tong M, Ma BBY, Hui EP, Shi L, King AD. A convolutional neural network combined with positional and textural attention for the fully automatic delineation of primary nasopharyngeal carcinoma on non-contrast-enhanced MRI. Quant Imaging Med Surg. 2021 Sep;11(9):3932-3944.

- Ng WT, Wong ECY, Cheung AKW, Chow JCH, Poon DMC et al. Patterns of care and treatment outcomes for local recurrence of NPC after definite IMRT-A study by the HKNPCSG. Head Neck. 2019 Jul 27
- Yip PL, Lee SF, Choi CH, Chan PS, Cheung KA, Chow CJ, Cheung KM, Lai WJ, Lee HV, Lam KO, Chiang CL, Wong CE, Poon MD, Tong M, Au KH, Ng WT, Ngan KR, Lee WA, Tung YS. External Validation of a Nomogram to Predict Survival and Benefit of Concurrent Chemoradiation for Stage II Nasopharyngeal Carcinoma. Cancers (Basel). 2021 Aug 25;13(17):4286.
- Stephen L Chan, Frankie Mo, Philip Johnson, Giok S Liem, Tung C Chan, Ming C Poon et al. Prospective validation of the Chinese University Prognostic Index and comparison with other staging systems for HCC in Asian populations. Journal of Gastroenterology and Hepatology 2011
- Chan SL, Mo FK, Wong VW, Liem GS, Wong GL, Chan VT, Poon DM, Loong HH, Yeo W, Chan AT, Mok TS, Chan HL. Use of antiviral therapy in surveillance: impact on outcome of hepatitis B-related hepatocellular carcinoma. Liver Int 2012
- Chan SL, Johnson PJ, Mo F, Berhane S, Teng M, Chan AW, Poon MC et al. International validation of the Chinese University Prognostic Index for staging of hepatocellular carcinoma: a joint United Kingdom and Hong Kong study. Chin J Cancer. 2014 Oct
- Chan SL, Chong CC, Chan AW, Poon DM, Chok KS. Management of hepatocellular carcinoma with portal vein tumor thrombosis: Review and update at 2016. World J Gastroenterol. 2016 Aug
- Cheung MLM, Kan MWK, Yeung VTY, Poon DMC, Kam MKM, Lee LKY, Chan ATC. Analysis of Hepatocellular Carcinoma Stereotactic Body Radiation Therapy Dose Prescription Method Using Uncomplicated Tumor Control Probability Model. Adv Radiat Oncol. 2021 Jun 12;6(5):100739
- Cheung MLM, Kan MW, Yeung VT, Poon DM, Kam MK, Lee LK, Chan AT. The effect on tumour control probability of using AXB algorithm in replacement of AAA for SBRT of hepatocellular carcinoma located at lung-liver boundary region. BJR Open. 2021 Nov 24;3(1):20210041.
- Danny TM Chan, Sonia YP Hsieh, Claire KY Lau, Michael KM Kam, Herbert HF Loong, WK Tsang, Darren MC Poon, WS Poon. Ten-year review of survival and management of malignant glioma in Hong Kong. HKMJ Dec 2016
- Hsieh SY, Chan DT, Kam MK, Loong HH, Tsang WK, Poon DM, Ng SC, Poon WS. Feasibility and safety of extended adjuvant temozolomide beyond six cycles for patients with glioblastoma. HKMJ Aug 2017

- Mok ST, Kam MK, Tsang WK, Poon DM et al. Frameless stereotactic radiosurgery for brain metastases: a review of outcomes and prognostic scores evaluation. Hong Kong Med J. 2017 Dec
- Tam KY, Lim K, Zhu CXL, Chan KY, Poon WS, Poon D et al. Long-term outcomes of ruptured cerebral arteriovenous malformations in the paediatric population: A retrospective review in a regional hospital in Hong Kong. J Clin Neurosci. 2019 Aug
- Aurora K Y Tam, David Y C Chan, Kevin Lim, Darren Poon et al. Long term treatment efficacy & complications of hypofractionated stereotactic radiosurgery in brain arteriovenous malformations. J Clin Neurosci 2020 Dec

Abstract presentation

- Darren MC Poon et al. Dosimetric Advantages And Superior Treatment Delivery Efficiency Of RapidArc Over Conventional Intensity-modulated Radiation Therapy In Radiation Therapy Planning For High Risk Prostate Cancer Involving Seminal Vesicles And Pelvic Nodes. Clin Oncol. 2013 Aug 15 (presented at *ASTRO* annual meeting 2011, Miami, USA)
- Darren MC Poon et al. The impact of image-guided radiotherapy (IGRT) for prostate cancer (PC) on radiotherapy (RT)-related acute toxicities and prostate-specific antigen (PSA) kinetics. J Clin Oncol 30, 2012 suppl; abstr e15110 (Presented as abstract at *ASCO* annual meeting 2012, Chicago, USA)
- Darren MC Poon et al. Intensity-modulated radiation therapy (IMRT) for prostate cancer: Toxicity and biochemical control in 183 Chinese patients from a single institution in Hong Kong. J Clin Oncol 29: 2011 (suppl 7; abstr 101) (Presented at *ASCO GU* cancer symposium 2011, Orlando, USA)
- Darren MC Poon et al. Application of abiraterone acetate (AA) in chemo-naïve metastatic castration-resistant prostate cancer (mCRPC) patients who did not fulfil the patient inclusion criteria in the COU-AA-302 study. J Clin Oncol 34, 2016 suppl 25; abstr 317 (Presented as abstract at *ASCO GU* cancer symposium 2016, San Francisco, USA)
- Darren MC Poon et al. The survival outcome, prostate-specific antigen (PSA) response and risk of fatigue of enzalutamide as first- and later-line treatment options in patients with metastatic castration-resistant prostate cancer (mCRPC): The real-world experience. J Clin Oncol 36, no. 6_suppl (February 20 2018) 330-330 (Presented as abstract at *ASCO GU* cancer symposium 2018, San Francisco, USA)

- Darren MC Poon et al. Stereotactic body radiotherapy (SBRT) versus conventional fractionated intensity-modulated radiotherapy (CF-IMRT) for Asian patients with early-stage localized prostate cancer: Acute toxicity results from a prospective randomized phase II study. *Annals of Oncology*, Volume 29, Issue suppl_9, 1 November 2018 (Presented as abstract at *ESMO Asia* 2018).

- Darren MC Poon et al. Stereotactic body radiotherapy (SBRT) versus conventional fractionated intensity-modulated radiotherapy (CF-IMRT) for patients with early-stage localized prostate cancer: One-year late toxicity results from a prospective randomized phase II study. *J Clin Oncol* 37, no. 7_suppl (Mar 1 2019) 27-27 (Presented as abstract at *ASCO GU* cancer symposium 2019, San Francisco, USA)

- Darren MC Poon et al. Treatment pattern and clinical outcomes of radium-223 (Ra223) in metastatic castration resistant prostate cancer (mCRPC): retrospective cohort analysis from Hong Kong. *Annals of Oncology* (2019) 30 (suppl_9): ix68-ix70 (Presented as abstract at *ESMO Asia* 2019).

- Darren MC Poon et al. Prevention of docetaxel-associated febrile neutropenia with primary granulocyte colony-stimulating factors (GCSF) in Chinese metastatic hormonal-sensitive (mHSPC) and castration-resistant prostate cancer (mCRPC). *J Clin Oncol* 38, no. 6_suppl (Feb 20 2020) 72-72 (Presented as abstract at *ASCO GU* cancer symposium 2020, San Francisco, USA)

- Darren MC Poon et al. Real-world utilization pattern of bone-targeted agents for metastatic prostate cancer: Web-based questionnaire study by Hong Kong Society of Uro-Oncology (HKSUO). *Annals of Oncology* (2020) 31 (suppl_6): S1325-S1333. (Presented in Mini-oral session at *ESMO Asia* 2020).

- Darren MC Poon et al. Palliative Radiotherapy for Patients with Locally-advanced or Metastatic Bladder Cancer. (Presented at Palliative care symposium for health care workers in Chinese population 2011)

Presentations & Lectures

Date	Meeting/Symposium	Topic
Nov 2013	Urology Symposium 2013, CUHK	Radiotherapy for prostate cancer – is the newer the better?
Sep 2014	Macau Urological Association Annual Scientific Meeting	Chemotherapy for metastatic prostate cancer – Right timing for right patients

Oct 2014	HKUA & HKSCO combined meeting	AUA index 6 patients
Nov 2014	Urology Symposium 2014, CUHK	Targeting on the bone problems in prostate cancer patients
Dec 2014	ENT Conference 2014, CUHK	Contemporary non-surgical management approach for locally advanced head and neck cancer
Jan 2015	2nd ICIC & HKCR Cancer imaging meeting: 'Cancer management: From diagnosis to treatment'	Radiotherapy for prostate cancer
Nov 2015	6th Joint Scientific Meeting of RCR & HKCR and 23rd Annual Scientific Meeting of HKCR	Contemporary radical radiotherapy for prostate cancer: from localized to locally advanced disease
Jan 2016	Hospital Authority (HK) commission training for urologist	Post-radical prostatectomy radiotherapy: Who? When? How?
Mar 2016	Asian Oncology Summit	Contemporary radical radiotherapy for prostate cancer: from localized to locally advanced disease
Apr 2016	Multi-specialty Medical Mega Conference 2016	The Evolving Role of Chemotherapy in Metastatic Prostate Cancer
Sep 2016	Macau Urological Association Annual Scientific Meeting	The contemporary management of castration-sensitive prostate cancer
Nov 2016	Urology Symposium 2016, CUHK	Systemic treatment for RCC – an update
Nov 2016	21 st Annual Scientific Symposium of the Hong Kong Cancer Institute: Immuno-Oncology Hong Kong 2016	Is it the primetime for immune-checkpoint inhibitors for urothelial carcinoma
Jan 2017	2 nd Annual Scientific Symposium of the Hong Kong Society of Uro-Oncology (HKSUO)	The contemporary management of castration-sensitive prostate cancer
Aug 2017	15th Urological Association of Asia	1. Asian Urology Residency Course:

	(UAA) Congress	<p>Immunotherapy for metastatic RCC</p> <ol style="list-style-type: none"> 2. Masterclass in kidney cancer: Managing complications associated with TKI in mRCC 3. Morning plenary: Advanced prostate cancer management - Hong Kong consensus statement by HKUA/HKSUO
Aug 2017	Taiwan Urology Association (TUA) 2017 Annual Meeting	Combination chemohormonal therapy for metastatic hormonal-sensitive prostate cancer
Nov 2017	Urology Symposium, CUHK	Is it the primetime for immune-checkpoint inhibitors for urothelial carcinoma
Sep 2018	Chinese prostate cancer summit 2018	Hong Kong's consensus
Oct 2018	Urology Symposium, CUHK	Current status of immunotherapy in urothelial carcinoma
Nov 2018	HKCR ASM 2018	Challenges and opportunities in implementing SBRT in a public hospital / Immunotherapy for RCC: Present and future
Dec 2018	Hospital Authority (HK) commission training for radiation therapists	The contemporary radiotherapy treatment for prostate cancer: Localize, locally-advanced to metastatic disease
Jan 2019	4th Annual Scientific Symposium of the Hong Kong Society of Uro-Oncology (HKSUO)	Immunotherapy for urothelial carcinoma: Metastatic disease and beyond
Jul 2019	Uro-Oncology MDT meeting, Hong Kong Sanatorium & Hospital	Management of prostate cancer in 2019 and beyond: From localized to metastatic disease
Aug 2019	The Hong Kong College of Otorhinolaryngologists: ENT training course	Primary treatment for NPC
Aug 2019	Advanced prostate cancer consensus conference (APCCC) 2019	Pharmaco-ethnicity and its impact on treatment
Aug 2019 / Mar 2021	ESMO Advanced Course on clinical questions in Prostate Cancer	<ol style="list-style-type: none"> 1. High risk localized disease: Integrating drugs with local treatments 2. Rising PSA: What to do? / non-metastatic mHSPC 3. Workshops sessions: Localized prostate cancer
Nov 2019	ESMO Asia 2019	Metastatic hormone-naïve prostate cancer: Radiation Oncology perspectives

Nov 2020	ESMO Asia 2020 Virtual	Ethnic differences (pharmacogenomic differences in Asian patients) in the management of metastatic prostate cancer
Nov 2021	ESMO Asia 2021 Virtual	Overview of neoadjuvant trials in MIBC New agents in metastatic disease

Clinical research (selected)

Study	Position
Capivasertib+Abiraterone as Treatment for Patients With Metastatic Hormone-sensitive Prostate Cancer and PTEN Deficiency (CAPItello-281)	Local site principal investigator
A phase III, multicenter, randomized, placebo-controlled, double-blind study of Atezoluzumab (Anti-PD-L1 Antibody) in combination with gemcitabine/carboplatin versus gemcitabine/carboplatin alone in patients with untreated locally advanced or metastatic urothelial carcinoma who are ineligible for cisplatin-based therapy (IMvigor-130)	Local site principal investigator
A Phase 2, Randomized, Open-Label Study of Nivolumab or Nivolumab/BMS-986205 Alone or Combined with Intravesical BCG in Participants with BCG-Unresponsive, High-Risk, Non-Muscle Invasive Bladder Cancer (NMIBC)	Local site principal investigator
Phase II Trial of Pembrolizumab (MK-3475) in Subjects with Metastatic Castration-Resistant Prostate Cancer (mCRPC) Previously Treated with Chemotherapy (KEYNOTE-199)	Local site principal investigator
A randomized, open label, multicenter phase 2/3 study to evaluate the efficacy and safety of rogaratinib (BAY 1163877) compared to chemotherapy in patients with FGFR-positive locally advanced or metastatic urothelial carcinoma who have received prior platinum-containing chemotherapy	Local site principal investigator
Randomized phase II study of combination androgen deprivation therapy (ADT) and radiotherapy in high risk prostate cancer: Stereotactic body Radiotherapy vs conventional IMRT to prostate and pelvic nodes (SRAM study)	Principal investigator
Phase II randomized trial for stereotactic body radiotherapy versus conventional IMRT in low or intermediate risk prostate cancer	Principal investigator

PSMA-PET guided Stereotactic Ablative Body Radiotherapy for Oligometastasis in metastatic castration-resistant prostate cancer (mCRPC) with progression on Enzalutamide (PMSABR study)	Principal investigator
Study of Cabozantinib in Combination with Nivolumab and Ipilimumab in Patients With Previously Untreated Advanced or Metastatic Renal Cell Carcinoma (COSMIC-313)	Local site principal investigator
An Open-label, Randomized Phase 3 Study of MK-6482 Versus Everolimus in Participants with Advanced Renal Cell Carcinoma That Has Progressed After Prior PD-1/L1 and VEGF-Targeted Therapies	Local site principal investigator
A Phase 3 Randomized, Double-Blind Study of Nivolumab or Placebo in Combination with Docetaxel, in Men with Metastatic Castration-resistant Prostate Cancer (CheckMate 7DX: CHECKpoint pathway and nivoluMAb clinical Trial Evaluation 7DX)	Local site principal investigator

Meeting/conference

Date	Meeting/conference	Position
Jan 2016	3 rd ACE Asia Pacific Prostate Cancer preceptorship program	Program chair
August 2016	Asia-Pacific Conference of Renal Cancer Experts (AP CORE) 2016	Program chair